JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Desta, Z.
Right arrow Articles by Flockhart, D. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desta, Z.
Right arrow Articles by Flockhart, D. A

Vol. 285, Issue 2, 428-437, May 1998

Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide1

Zeruesenay Desta, Thomas Kerbusch, Nadia Soukhova, Emily Richard, Jae-Wook Ko and David A Flockhart

Division of Clinical Pharmacology, Department of Medicine and Pharmacology, Georgetown University Medical Center, Washington, DC

Using human liver microsomes (HLMs) and recombinant human cytochrome P450 (CYP450) isoforms, we identified the major route of pimozide metabolism, the CYP450 isoforms involved, and documented the inhibitory effect of pimozide on CYP450 isoforms. Pimozide was predominantly N-dealkylated to 1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one (DHPBI). The formation rate of DHPBI showed biphasic kinetics in HLMs, which suggests the participation of at least two activities. These were characterized as high-affinity (Km1 and Vmax1) and low-affinity (Km2 and Vmax2) components. The ratio of Vmax1 (14 pmol/min/mg protein)/Km1 (0.73 µM) was 5.2 times higher than the ratio of Vmax2 (244 pmol/min/mg protein)/Km2 (34 µM). Km2 was 91 times higher than Km1. The formation rate of DHPBI from 25 µM pimozide in nine human livers correlated significantly with the catalytic activity of CYP3A (Spearman r = 0.79, P = .028), but not with other isoforms. Potent inhibition of DHPBI formation from 10 µM pimozide was observed with ketoconazole (88%), troleandomycin (79%), furafylline (48%) and a combination of furafylline and ketoconazole (96%). Recombinant human CYP3A4 catalyzed DHPBI formation from 10 µM pimozide at the highest rate (V = 2.2 ± 0.89 pmol/min/pmol P450) followed by CYP1A2 (V = 0.23 ± 0.08 pmol/min/pmol P450), but other isoforms tested did not. The Km values derived with recombinant CYP3A4 and CYP1A2 were 5.7 µM and 36.1 µM, respectively. Pimozide itself was a potent inhibitor of CYP2D6 in HLMs when preincubated for 15 min (Ki = 0.75 ± 0.98 µM) and a moderate inhibitor of CYP3A (Ki = 76.7 ± 34.5 µM), with no significant effect on other isoforms tested. Our results suggest that pimozide metabolism is catalyzed mainly by CYP3A, but CYP1A2 also contributes. Pimozide metabolism is likely to be subject to interindividual variability in CYP3A and CYP1A2 expression and to drug interactions involving these isoforms. Pimozide itself may inhibit the metabolism of drugs that are substrates of CYP2D6.

0022-3565/98/2852-0428$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Jeong, P. D. Nguyen, and Z. Desta
Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A
Antimicrob. Agents Chemother., February 1, 2009; 53(2): 541 - 551.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
N. B. Sandson, S. C. Armstrong, and K. L. Cozza
An Overview of Psychotropic Drug-Drug Interactions
Psychosomatics, October 1, 2005; 46(5): 464 - 494.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. A. Ray, K. T. Murray, S. Meredith, S. S. Narasimhulu, K. Hall, and C. M. Stein
Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes
N. Engl. J. Med., September 9, 2004; 351(11): 1089 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. A. Ward, J. C. Gorski, D. R. Jones, S. D. Hall, D. A. Flockhart, and Z. Desta
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 287 - 300.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. Scahill, J.F. Leckman, R.T. Schultz, L. Katsovich, and B.S. Peterson
A placebo-controlled trial of risperidone in Tourette syndrome
Neurology, April 8, 2003; 60(7): 1130 - 1135.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Z. Desta, G. M. Wu, A. M. Morocho, and D. A. Flockhart
The Gastroprokinetic and Antiemetic Drug Metoclopramide Is a Substrate and Inhibitor of Cytochrome P450 2D6
Drug Metab. Dispos., March 1, 2002; 30(3): 336 - 343.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
B. Drolet, G. Rousseau, P. Daleau, R. Cardinal, C. Simard, and J. Turgeon
Pimozide (Orap(R)) Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current in Native Cardiac Myocytes
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 255 - 260.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Z. Desta, N. Soukhova, A. M Morocho, and D. A Flockhart
Stereoselective Metabolism of Cisapride and Enantiomer-Enantiomer Interaction in Human Cytochrome P450 Enzymes: Major Role of CYP3A
J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 508 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. A. Bruce, S. D. Hall, B. D. Haehner-Daniels, and J. C. Gorski
In Vivo Effect of Clarithromycin on Multiple Cytochrome P450s
Drug Metab. Dispos., July 1, 2001; 29(7): 1023 - 1028.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Z. Desta, N. V. Soukhova, and D. A. Flockhart
Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A
Antimicrob. Agents Chemother., February 1, 2001; 45(2): 382 - 392.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
Z. Desta, N. Soukhova, S. K. Mahal, and D. A. Flockhart
Interaction of Cisapride with the Human Cytochrome P450 System: Metabolism and Inhibition Studies
Drug Metab. Dispos., July 1, 2000; 28(7): 789 - 800.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
L. C. Wienkers, C. Allievi, M. J. Hauer, and M. A. Wynalda
Cytochrome P-450-Mediated Metabolism of the Individual Enantiomers of the Antidepressant Agent Reboxetine in Human Liver Microsomes
Drug Metab. Dispos., November 1, 1999; 27(11): 1334 - 1340.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
J.-G. Shin, N. Soukhova, and D. A. Flockhart
Effect of Antipsychotic Drugs on Human Liver Cytochrome P-450 (CYP) Isoforms In Vitro: Preferential Inhibition of CYP2D6
Drug Metab. Dispos., September 1, 1999; 27(9): 1078 - 1084.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.